The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Expanding isatuximab treatment beyond hospital settings with an on-body injector
Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses the potential role of the isatuximab subcutaneous formulation with an on-body injector (OBI) in expanding treatment beyond hospital-based settings. He highlights Phase II experience showing that the device can be implemented across academic and community centers with appropriate physician and nurse training, and discusses its potential to facilitate home-based treatment. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The isatuximab subcutaneous formulation plus the OBI, it doesn’t need much nurse experience, nurse training, doesn’t need much pharmacist issues, and the patients can very rapidly adopt and learn on their own how to use the product so my understanding is that and my experience in France in my country using this is that and in our study actually in our study isatuximab we had academic centers and community best centers and and the way the drug was used the way the device OBI was used and how long it took for the centers to know how to do it right was very much the same there was no difference across centers so the the use of that device needs a trained physician and or a trained nurse to train the patient...
The isatuximab subcutaneous formulation plus the OBI, it doesn’t need much nurse experience, nurse training, doesn’t need much pharmacist issues, and the patients can very rapidly adopt and learn on their own how to use the product so my understanding is that and my experience in France in my country using this is that and in our study actually in our study isatuximab we had academic centers and community best centers and and the way the drug was used the way the device OBI was used and how long it took for the centers to know how to do it right was very much the same there was no difference across centers so the the use of that device needs a trained physician and or a trained nurse to train the patient. But there is no reason to believe that in a community-based hospital, the nurse would not be able to learn how to do it right, or the physician would not understand how to do it right, because it’s just a technical thing. There is nothing special with it. So in our experience in France, and particularly in this phase two study up front, isatuximab we demonstrated that if you have one physician trained and one nurse trained, it’s applicable to almost all centers, all patients. No difference expected. So I do not see why in the community hospital it would be difficult to use isatuximab subcutaneous formulation with the OBI. And actually, I’m anticipating that it would not even be a community-based thing that most of the patients, a great number, sorry, of the patients may actually be treated at home. So it’s not even a community-based thing versus academic. It’s even farther than that. It’s home-based treatment. So, oh yeah, it’s very easy to manage, very easy to learn.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
